Healthcare Industry News: S.A.
News Release - April 2, 2012
NicOx appoints Philippe Masquida EVP, Managing Director of European Operations ; Next step in the Company's strategy to create an international ophthalmology company
SOPHIA ANTIPOLIS CEDEX, FRANCE--(Healthcare Sales & Marketing Network)-NicOx S.A. (NYSE Euronext Paris: COX) today announces the appointment of Philippe Masquida as Executive Vice President, Managing Director of European Operations. Mr. Masquida has over 22 years of senior international pharmaceutical experience and an impressive track record in ophthalmology.Mr. Masquida will lead NicOx's operations in Europe and in this role he will be managing the European subsidiaries. In addition he will be responsible, in coordination with the executive team of NicOx, for identifying and evaluating commercial opportunities in Europe as part of the Company's strategy to build a late-S.A.e ophthalmic portfolio. He will be part of NicOx's Executive Committee and report to Michele Garufi, Chairman and CEO.
Mr. Masquida joins NicOx from Pierre Fabre where he was Vice President, Head of International Operations, Pharmaceuticals, and was responsible for 25 affiliates in Europe, AS.A. Americas, Middle East and Africa, employing around 1,600 people. Prior to this he spent 7 yearS.A. Allergan Inc., where he successfully led the growth of the Company's Emerging Markets in Europe, Africa and the Middle East, including in ophthalmology. He also held the position of Director of International Affairs for 8 yearS.A. Laboratoires Théa, an independent pharmaceutical company specialized in ophthalmology, where he was instrumental in the eS.A.lishment of a number of European subsidiarieS.A.d was responsible for international business. Mr. Masquida has previously held a number of positionS.A. Sanofi Aventis (Fisons) and Merck Inc.
On March 21, 2012, NicOx announced a strategy to create an international, late-S.A.e development and commercial ophthalmology company based around therapeutics, diagnosticS.A.d devices. The appointment of Mr. Masquida iS.A.key part of this strategy and follows the appointment of Jerry St. Peter in the United S.A.es. AS.A.first step in this transformation, NicOx haS.A.quired 11.8% of the S.A.es of Altacor, a privately-held ophthalmology company based in the United Kingdom, and entered into an exclusive option agreement to acquire the remaining S.A.es of Altacor. NicOx haS.A.number of other opportunities currently under discussion which could lead to additional M&A or in-licensing to build a balanced ophthalmology pipeline across the United S.A.eS.A.d Europe.
Michele Garufi, Chairman and CEO of NicOx, said: "The appointment of Philippe Masquida iS.A.other significant step forward in our strategy to create an international late-S.A.e development and commercial ophthalmology company. He bringS.A.wealth of business management skillS.A.d extensive experience in Ophthalmology, which will be of significant value as we continue to build a diverse late-S.A.e portfolio in ophthalmology with a clear route to commercialisation."
Philippe Masquida commented: "The ophthalmology market is experiencing significant growth and there iS.A.real opportunity for NicOx to become an international, mid-sized player to occupy the S.A.e between big pharma and local players. With its existing expertise and clear growth strategy, I believe NicOx is well placed to take full advantage of these opportunitieS.A.d I look forward to working with the team as we create a global ophthalmology company."
About NicOx
NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is building an international late-S.A.e development and commercial Ophthalmology Company based around therapeutics, diagnosticS.A.d devices. As of March 2012, NicOx holdS.A. 11.8% S.A.e in the UK-based ophthalmology company Altacor, with an option to acquire the remaining S.A.es, as the first step of a transformation into a late-S.A.e development and commercial ophthalmic Company.
NicOx iS.A.so developing an internal portfolio of New Molecular Entities (NMEs) through the application of its proprietary nitric oxide-donating R&D platform. The Company's pipeline includes several nitric oxide-donating NMEs for the potential treatment of ophthalmological, inflammatory and cardio-metabolic diS.A.es, which are in development internally and with partners, who include Bausch + Lomb, Merck (known as MSD outside theUnited S.A.eS.A.dCanada) and Ferrer.
NicOx S.A. is headquartered in France and is listed on Euronext Paris (Compartment C: S.A.l Caps).
This press release contains certain forward-looking S.A.ements. Although the Company believes its expectationS.A.e based on reasonable assumptions, these forward-looking S.A.ementS.A.e subject to numerous riskS.A.d uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking S.A.ements.
Risks factors which are likely to have a material effect on NicOx's businesS.A.e presented in the 4(th) chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2011 » filed with the French Autorité des Marchés Financiers (AMF) on February 29, 2012 and available on NicOx's website (www.nicox.com) and on the AMF's website (www.amf-france.org).
NicOx S.A.
Les Taissounières - Bât HB4 - 1681 route des Dolines - BP313 - 06906 Sophia Antipolis Cedex - France Tel: +33 (0)4 97 24 53 00 • Fax: +33 (0)4 97 24 53 99
Source: NICOX
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!